These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 27976465)

  • 21. Clinical factors predicting the therapeutic response to ustekinumab in patients with moderate to severe chronic plaque psoriasis.
    Hwang YJ; Youn SW; Kim BR; Yu DY; Kim Y; Pires A; Cho S; Seo SJ; Lee ES; Roh JY; Choi GS; Lee MG;
    J Dermatol; 2017 May; 44(5):560-566. PubMed ID: 27864841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
    Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
    J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis.
    Mugheddu C; Atzori L; Del Piano M; Lappi A; Pau M; Murgia S; Zucca I; Rongioletti F
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28833973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nail Psoriasis: An Updated Review and Expert Opinion on Available Treatments, Including Biologics.
    Bardazzi F; Starace M; Bruni F; Magnano M; Piraccini BM; Alessandrini A
    Acta Derm Venereol; 2019 May; 99(6):516-523. PubMed ID: 30521057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of ustekinumab for the treatment of psoriasis vulgaris with myotonic dystrophy.
    Fujita Y; Shinkuma S; Nomura T; Shimizu H
    Eur J Dermatol; 2016 Apr; 26(2):187-8. PubMed ID: 26643260
    [No Abstract]   [Full Text] [Related]  

  • 26. Ustekinumab treatment in patients with psoriasis undergoing hemodialysis.
    Umezawa Y; Hayashi M; Kikuchi S; Fukuchi O; Yanaba K; Ito T; Asahina A; Saeki H; Nakagawa H
    J Dermatol; 2015 Jul; 42(7):731-4. PubMed ID: 25959602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis.
    Tzung TY; Chen CY; Yang CY; Lo PY; Chen YH
    Acta Derm Venereol; 2008; 88(3):279-80. PubMed ID: 18480933
    [No Abstract]   [Full Text] [Related]  

  • 28. Nail psoriasis: a review.
    Tan ES; Chong WS; Tey HL
    Am J Clin Dermatol; 2012 Dec; 13(6):375-88. PubMed ID: 22784035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tacalcitol ointment for the treatment of nail psoriasis.
    Márquez Balbás G; Sánchez Regaña M; Umbert Millet P
    J Dermatolog Treat; 2009; 20(5):308-10. PubMed ID: 19367480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pregnancy during Ustekinumab Treatment for Severe Psoriasis.
    Rocha K; Piccinin MC; Kalache LF; Reichert-Faria A; Silva de Castro CC
    Dermatology; 2015; 231(2):103-4. PubMed ID: 25790947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful ustekinumab treatment in a patient with psoriasis and subacute cutaneous lupus erythematosus.
    Mazgaj M; Picard-Dahan C; Deschamps L; Marinho E; Estève E; Descamps V
    Int J Dermatol; 2020 Apr; 59(4):e118-e120. PubMed ID: 31957866
    [No Abstract]   [Full Text] [Related]  

  • 32. An analysis of Drug Survival, Effectiveness, and Safety in Moderate to Severe Psoriasis Treated With Ustekinumab: An Observational Study of 69 Patients in Routine Clinical Practice.
    Salgüero Fernández I; Gil MH; Sanz MS; Gullón GR
    Actas Dermosifiliogr (Engl Ed); 2019 Apr; 110(3):244-246. PubMed ID: 29961546
    [No Abstract]   [Full Text] [Related]  

  • 33. Case of psoriatic patient who maintains long-term remission after anti-hepatitis C virus agents and ustekinumab treatment.
    Kikuchi S; Umezawa Y; Chihara M; Asahina A; Nakagawa H
    J Dermatol; 2018 Mar; 45(3):e59-e60. PubMed ID: 29388245
    [No Abstract]   [Full Text] [Related]  

  • 34. Brodalumab versus ustekinumab in psoriasis.
    Fioranelli M; Roccia MG; Lotti T
    Dermatol Ther; 2016 Sep; 29(5):298. PubMed ID: 26627075
    [No Abstract]   [Full Text] [Related]  

  • 35. Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab.
    Hesselvig JH; Egeberg A; Loft ND; Zachariae C; Kofoed K; Skov L
    Acta Derm Venereol; 2018 Mar; 98(3):335-339. PubMed ID: 29110019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A case of nail psoriasis treated with topical calcitriol.
    Usmani N; Wilson C
    Clin Exp Dermatol; 2006 Sep; 31(5):712-3. PubMed ID: 16901318
    [No Abstract]   [Full Text] [Related]  

  • 37. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study.
    Patsatsi A; Kyriakou A; Sotiriadis D
    J Dermatolog Treat; 2013 Apr; 24(2):96-100. PubMed ID: 21797806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis.
    Loget J; Plée J; Antonicelli F; Bernard P
    J Eur Acad Dermatol Venereol; 2017 May; 31(5):e228-e230. PubMed ID: 27730667
    [No Abstract]   [Full Text] [Related]  

  • 39. Exacerbation of systemic lupus erythematosus in a patient with concomitant chronic plaque psoriasis treated with ustekinumab.
    Goh SW; Jamil A; Nor NM; Cader RA; Shaharir SS
    Indian J Dermatol Venereol Leprol; 2020; 86(1):68-70. PubMed ID: 31823905
    [No Abstract]   [Full Text] [Related]  

  • 40. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
    Elewski BE; Okun MM; Papp K; Baker CS; Crowley JJ; Guillet G; Sundaram M; Poulin Y; Gu Y; Geng Z; Williams DA; Rich PA
    J Am Acad Dermatol; 2018 Jan; 78(1):90-99.e1. PubMed ID: 28993005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.